The choice of melanoma derives from our recent study, which indicates that NAMPT becomes the dominant NAD-biosynthetic enzyme in BRAF-resistant melanoma cell lines and patients BRAF-mutated [22]. This evidence concerns the gene BRAF and melanoma.